Email address
[email protected]Contact number
+1.617.948.6032Share profile
Band 1
Band 1
Band 2
Band 4
Band 4
About
Provided by John Chory
Practice Areas
John Chory retired from the partnership in December 2023 and is currently of counsel. John represents technology and life sciences companies from startup through IPO. He is the former Global Chair of the firm's Emerging Companies & Growth Practice.
John advises both private and public companies in the following areas:
- Early-stage company formation and strategy
- Initial- through late-stage venture capital financings
- Public offerings of securities
- Mergers and acquisitions
- Technology licensing
- Securities law
John lectures frequently on legal issues facing emerging companies. He is an Xconomist.
While at Harvard, John taught negotiation as a teaching assistant to Roger Fisher, author of “Getting to Yes.” Prior to attending law school, he was a US Army intelligence officer.
Chambers Review
USA
John Chory frequently advises on complex venture financing and M&A. He has a wealth of experience in the Boston technology market and his clients range from emerging companies to public corporations. He chairs the firm's emerging companies practice group.
John Chory is a widely respected corporate attorney whose multifaceted practice features strengths across M&A, capital markets and venture capital work. He acts on behalf of both investors and early-stage companies, particularly in the technology sector.
John Chory is the global chair of the firm's emerging companies practice. He has substantial experience of providing counsel to fintech and life science companies from inception through to IPOs.
John Chory is an expert in advising emerging companies in the technology industry on matters ranging from business formation to venture capital financing, IPOs and M&A. He benefits from parallel experience in advising startups on technology licensing and securities law.
John Chory is recognized as an industry-leading expert in the technology sector, where he advises clients on a broad spectrum of commercial, regulatory and corporate law matters. He regularly acts for both emerging and mature businesses in the technology and life sciences sectors.